Molecular Pharmacology Program

The Ronald Blasberg Lab

Research

Ronald G. Blasberg, MD

Ronald Blasberg’s laboratory in the Molecular Pharmacology Program focuses on the development of preclinical, noninvasive, multimodality reporter-gene imaging and its translation into a clinical application. These approaches utilize modern molecular biology, cancer biology, and imaging (MRI, optical imaging, PET, and SPECT) techniques.

View Lab Overview

Research Projects

Noninvasive Transgene Imaging

Publications

Huang R, Vider J, Kovar JL, Olive DM, Mellinghoff IK, Mayer-Kuckuk P, Kircher MF, Blasberg RG. Integrin αvβ3-targeted IRDye 800CW near-infrared imaging of glioblastoma. Clin Cancer Res. 2012 Oct 15;18(20):5731-40. doi: 10.1158/1078-0432.CCR-12-0374. Epub 2012 Aug 22.

Serganova I, Rizwan A, Ni X, Thakur SB, Vider J, Russell J, Blasberg R, Koutcher JA. Metabolic imaging: a link between lactate dehydrogenase A, lactate, and tumor phenotype. Clin Cancer Res. 2011 Oct 1;17(19):6250-61. doi: 10.1158/1078-0432.CCR-11-0397. Epub 2011 Aug 15.

Huang R, Cheung NK, Vider J, Cheung IY, Gerald WL, Tickoo SK, Holland EC, Blasberg RG. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas. FASEB J. 2011 Dec;25(12):4138-49. doi: 10.1096/fj.11-185033. Epub 2011 Aug 19.

Moroz E, Carlin S, Dyomina K, Burke S, Thaler HT, Blasberg R, Serganova I. Real-time imaging of HIF-1alpha stabilization and degradation. PLoS One. 2009;4(4):e5077. doi: 10.1371/journal.pone.0005077. Epub 2009 Apr 4.

Serganova I, Moroz E, Vider J, Gogiberidze G, Moroz M, Pillarsetty N, Doubrovin M, Minn A, Thaler HT, Massague J, Gelovani J, Blasberg R. Multimodality imaging of TGFbeta signaling in breast cancer metastases. FASEB J. 2009 Aug;23(8):2662-72. doi: 10.1096/fj.08-126920. Epub 2009 Mar 26.

View All Publications

People

Ronald G. Blasberg, MD

Physician-scientist Ronald Blasberg focuses on the development of noninvasive imaging paradigms in living organisms using radionuclide and optical reporter systems.
MD, Albert Einstein College of Medicine

blasberr@mskcc.org: Email Address
646-888-2211: Office Phone

Members

Inna S. Serganova
Senior Research Scientist

Alexandra Bennion

Intern

Danielle Castro

Intern

Maya Lee

Intern

Patty Medina

Intern

Mahnue Sahn

Intern

Anmol Surpur

Intern

Sebastian Velez

Intern

Lab Alumni

Ekaterina Moroz

Visiting Investigator

Teja Kalidindi

Intern

Sandhya Chalasani

Visiting Researcher

Masatomo Maeda, MD — Masatomo Maeda
Research Fellow

Jelena Vider

Visiting Investigator

David Sardar

Volunteer

Portia Cummings

Intern

Kiana Gregorio

Office Coordinator

Kelly Kang

Intern

Renata Martin

Summer Intern (2013)

Tanner Nickles

Intern

Masahiro Shindo
Visiting Research Scientist

Lab Affilations

Achievements

Paul C. Aebersold Award for Outstanding Achievement in Basic Nuclear Medicine Science, Society of Nuclear Medicine (2008)
Honorary Doctoral Degree in Medical Sciences, University of Copenhagen (2005)

Get in Touch

blasberr@mskcc.org

Lab Head Email
646-888-2211

Office Phone
646-422-0408

Office Fax
646-888-2218/2219

Lab Phone
646-422-0408

Lab Fax

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Ronald G. Blasberg discloses the following relationships and financial interests:

No disclosures meeting criteria for time period

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.

View all disclosures